论文部分内容阅读
2016年10月19日,清华大学宣布,该校罗永章团队在世界上首次证明,肿瘤标志物热休克蛋白90α(Hsp90α)可用于肝癌患者的检测,这意味着仅需要少量血液或者其他体液就可以检测到早期肝癌的踪迹,肝癌患者的早期发现率与生存率可以大大提高。国家食品药品监督管理总局批准血浆Hsp90α用作肝癌标志物,标志着首个由我国科学家定义并获准用于临床的广谱肿瘤标志物的诞生,对提高癌症诊疗水平具有深远的
On October 19, 2016, Tsinghua University announced that the school’s Luo Yongzhang team has demonstrated for the first time in the world that the tumor marker heat shock protein 90α (Hsp90α) can be used in the detection of liver cancer patients, which means that only a small amount of blood or other body fluids can be needed Detection of early traces of liver cancer, liver cancer patients early detection rate and survival rate can be greatly enhanced. The State Food and Drug Administration approved the use of plasma Hsp90α as a marker of liver cancer, marking the birth of a broad spectrum of tumor markers, first defined by our scientists and approved for clinical use, and of far reaching importance in improving the diagnosis and treatment of cancer